急性冠脉综合征后疑似阿司匹林抵抗患者的阿司匹林剂量:ANDAMAN 试验
ANDAMAN 试验为前瞻性多中心随机试验,纳入 2484 例急性冠脉综合征合并糖尿病或阿司匹林抵抗高危因素的患者,比较每日两次与每日一次肠溶阿司匹林。结果显示两组主要不良心血管事件及大出血发生率均无显著差异。
要点
- ACS 合并 DM 或阿司匹林抵抗高危者,每日两次阿司匹林未显著降低 MACE。
- 每日两次与每日一次阿司匹林的大出血风险相似。
- 该人群缺血事件复发率仍较高,需探索其他抗栓策略。
核心结论
- 在 ACS 合并 DM 或阿司匹林抵抗高危患者中,每日两次阿司匹林较每日一次未显著降低 MACE 风险。
- 两组大出血发生率无显著差异。
研究设计与样本
- 前瞻性多中心随机试验,纳入 2484 例 ACS 合并 DM 或阿司匹林抵抗高危(HRAR)患者。
- HRAR 定义包括:服用阿司匹林期间发生索引事件、BMI≥27 kg/m2 或腰围增加。
- 随机接受肠溶阿司匹林每日一次(100 mg/天)或每日两次(早晚各 100 mg)。
- 主要终点为 MACE 复合终点,采用首次事件时间分析;主要次要终点为大出血(BARC 3-5 型)。
- 中位随访 18 个月(IQR 17.6-18.3)。
主要发现
- 大出血发生率两组相似(1.9% vs 2.1%;HR 0.88;95%CI 0.50-1.55)。
- 纳入人群中 77.2% 合并 DM,55.5% 为 ST 段抬高型心肌梗死。
临床怎么用
- 对于 ACS 合并 DM 或阿司匹林抵抗高危患者,每日两次阿司匹林未能显著减少 MACE,不支持常规采用该策略。
- 每日两次阿司匹林未增加大出血风险,但需结合个体情况权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Despite current antithrombotic treatments, the recurrence of ischaemic events remains high in patients with diabetes mellitus (DM) or aspirin resistance after acute coronary syndrome (ACS). Whether twice-daily aspirin dosing reduces major adverse cardiovascular events (MACE) in this population remains unknown. METHODS: In this prospective multicentre, randomized trial, patients with ACS and DM or high-risk of aspirin resistance (HRAR) defined as: (i) an index event occurring while on aspirin; (ii) body mass index ≥27 kg/m2; or (iii) increased waist circumference were assigned to receive enteric-coated aspirin once daily (100 mg/day) or twice daily (100 mg morning and evening). The primary outcome was MACE, a composite of any death, myocardial infarction, stroke, urgent coronary revascularization, stent thrombosis, or acute arterial thrombotic event assessed using a time-to-first-event analysis. The main secondary outcome was major bleeding (Bleeding Academic Research Consortium type 3-5). RESULTS: In total, 2484 participants were enrolled (77.2% with DM, 55.5% with ST-elevation segment myocardial infarction). The median follow-up duration was 18 (interquartile range: 17.6-18.3) months. The primary outcome occurred in 95 of 1228 participants (7.7%) in the twice-daily aspirin group, and 110 of 1256 (8.8%) in the once-daily group (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.69-1.19; P = .42). Major bleeding rates were similar between the groups (1.9% vs 2.1%; HR 0.88; 95% CI 0.50-1.55). CONCLUSIONS: In patients with ACS and DM or HRAR, twice-daily aspirin did not significantly reduce the risk of MACE compared to once-daily dosing. No significant difference was observed in major bleeding between groups. TRIAL REGISTRATION: NCT02520921/EUDRACT No: 2015-000947-18.
引用
- Dillinger, Pezel, Batias, et al. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. Eur Heart J. 2026. PMID: 40884757. doi:10.1093/eurheartj/ehaf680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。